Despite a vast body of work investigating the function of this protein in recent years, only one JMJD3/UTX binder (GSK‐J1) has been reported to date.1 Recently, a series of GSK‐J1 derivatives was reported, showing activity similar to or lower than that of the reference compound.10 Thus, the discovery of small molecules that are able to selectively modulate the biological function of JMJD3 is very attractive, in that they will shed light on its role, both in normal biological processes and under disease conditions, expanding the cancer therapy toolkit. Here, KDM6B is linked to cancer.